Stay updated on ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page
- Check7 days agoChange DetectedThe page revision line was updated from v3.5.4 to v3.5.5, indicating a new site deployment rather than changes to the study details.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe revision label at the bottom of the page updated from v3.5.3 to v3.5.4, indicating a site deployment. This update does not alter the study details or user-facing functionality.SummaryDifference0.0%

- Check49 days agoChange DetectedThe page’s displayed software/version label has been updated from **Revision v3.5.2** to **Revision v3.5.3**, indicating an interface or site release update without affecting the underlying study record content.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded the new study title A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer (MUIR) and expanded the description of the Phase 1b study design, including Part 1 and Part 2, dose escalation and expansion with bevacizumab. Updated the page to Completed status with an enrollment target of 172 and a primary completion date of 2028-06-30, replacing the previous version.SummaryDifference3%

- Check85 days agoChange DetectedRevision v3.5.0 was added and v3.4.3 was removed.SummaryDifference0.0%

Stay in the know with updates to ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page.